Biotechnology
COVID ‘Compromise’ on International IP Underscores Need for New Approach
For COVID treatments and diagnostics to be broadly available at affordable prices, their IP must be considered a global public good.
COVID ‘Compromise’ on International IP Underscores Need for New Approach
